Publication Name	World Journal of Clinical Oncology
Manuscript ID	26720
Country	Greece

Received	2016-04-23 15:17
Peer-Review Started	2016-04-23 20:47
To Make the First Decision	2016-06-06 10:42
Return for Revision	2016-06-07 10:38
Revised	2016-06-15 15:44
Second Decision	2016-07-15 16:50
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2016-07-22 12:07
Articles in Press	2016-07-22 12:07
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-26 15:12
Publish the Manuscript Online	2016-08-01 09:43

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Obstetrics & Gynecology
Manuscript Type	Systematic Reviews
Article Title	Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials
Manuscript Source	Invited Manuscript
All Author List	Menelaos Zafrakas, Panayiota Papasozomenou and Christos Emmanouilides
Funding Agency and Grant Number
Corresponding Author	Menelaos Zafrakas, FEBS (Breast Surgery), Professor of Obstetrics and Gynecology, Research Laboratory for Mastology, Gynecology and Obstetrics, School of Health and Medical Care, Alexander Technological Institute of Thessaloniki, Ethnikis Antistaseos 81, 57400 Thessaloniki, Greece. mzafrakas@gmail.com
Key Words	Breast cancer; Sorafenib; Kinase inhibitors; BRAF; Mitogen-activated protein kinase
Core Tip	In this systematic review of the literature, the role of sorafenib in the treatment of breast cancer has been evaluated. Regarding toxicity, sorafenib was generally well tolerated in breast cancer patients, while in terms of efficacy the most promising results came from clinical trials evaluating sorafenib in combination with gemcitabine and/or capecitabine and possibly tamoxifen. Efficacy was inadequate with sorafenib monotherapy and combinations with taxanes, bevacizumab and ixabepilone.
Publish Date	2016-08-01 09:43
Citation	Zafrakas M, Papasozomenou P, Emmanouilides C. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World J Clin Oncol 2016; 7(4): 331-336
URL	http://www.wjgnet.com/2218-4333/full/v7/i4/331.htm
DOI	http://dx.doi.org/10.5306/wjco.v7.i4.331

Full Article (PDF)	WJCO-7-331.pdf
Full Article (Word)	WJCO-7-331.doc
Manuscript File	26720-Review.docx
Answering Reviewers	26720-Answering reviewers.pdf
Audio Core Tip	26720-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	26720-Conflict-of-interest statement.pdf
Copyright License Agreement	26720-Copyright assignment.pdf
Peer-review Report	26720-Peer-review(s).pdf
Scientific Misconduct Check	26720-Scientific misconduct check.pdf
Scientific Editor Work List	26720-Scientific editor work list.pdf